Oxidative Stress in Hemodialysis Patients: Pathophysiological Mechanisms, Clinical Consequences and basic Principles of Treatment
References
- Cozzolino M, Mangano M, Stucchi A, et al. (2018). Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 33(1), 28–34. DOI: 10.1093/ndt/gfy174.
- Zoccali C, Mallamaci F, Tripepi G. (2004). Novel Cardiovascular Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol. 15(Suppl 1), 77–80. DOI: 10.1097/01.ASN.0000093240.84097.FE.
- Locatelli F, Canaud B, Eckardt K-U, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272–80. DOI: 10.1093/ndt/gfg074.
- Descamps-Latscha B, Drüeke T, Witko-Sarsat V. (2001). Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 14(3), 793–9. DOI: 10.1046/j.1525-139X.2001.00052.x.
- Liakopoulos V, Roumeliotis S, Gorny X, et al. (2017). Oxidative Stress in Hemodialysis Patients: A Review of the Literature. Oxidative Med Cell Long. 2017: 3081856., DOI: 10.1155/2017/3081856.
- Santoro A, Guadagni G. (2010). Dialysis membrane: from convection to adsorption. Nephrol Dial Transplant. 3(Suppl 1), 36–9. DOI: 10.1093/ndtplus/sfg035.
- Ronco C, Clark W. Hemodialysis membranes. (2018). Nat Rev Nephrol. 14(6), 394–410. DOI: 10.1038/s41581-018-0002-x.
- Wu CC, Chen JS, Wu WM, et al. (2005). Myeloperoxidase serves as a marker of oxidative stress during single hemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 20(6), 1134–9. DOI: 10.1093/ndt/gfh764.
- Ward RA. Ultrapure Dialysate. (2004). Semin Dial. 17(6), 489–97. DOI: 10.1111/j.0894-0959.2004.17617.x.
- Glorieux G, Neirynck N, Veys N, et al. (2012). Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant. 27(11), 4010–21. DOI: 10.1093/ndt/gfs306.
- Aziz MA, Majeed GH, Diab KS, et al. (2016). The association of oxidant-antioxidant status in patients with chronic renal failure. Ren Fail. 38(1), 20–6. DOI: 10.3109/0886022X.2015.1103654.
- Handelman GJ. (2007). Vitamin C deficiency in dialysis patients - are we perceiving the tip of an iceberg? Nephrol Dial Transplant. 22(2), 328–31. DOI: 10.1093/ndt/gfl534.
- Zalba G, Fortuño A, Diez J. (2006). Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant. 21(10), 2686–90. DOI: 10.1093/ndt/gfl398.
- Massy ZA. (2000). Importance of homocystein, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant. 15(Suppl 5), 81–91. DOI: 10.1093/ndt/15.suppl_5.81.
- Culleton BF, Bostom AG. (2000). Hyperhomocysteinemia in chronic renal disease. In: Cardiovascular Disease in End-stage Renal Failure. Loscalzo J, London GM, (eds). The Oxford University Press, New York, 2000: 211–28.
- Kielstein JT, Frölich JC, Haller H, et al. (2001). ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patient with renal disease? Nephrol Dial Transplant. 16(9), 1742–5. DOI: 10.1093/ndt/16.9.1742.
- Lacson E, Levin NW. (2004). C-Reactive Protein and End-Stage Renal Disease. Semin Dial. 17(6), 438–48. DOI: 10.1111/j.0894-0959.2004.17604.x.
- Petrović D, Obrenović R, Poskurica M, i ost. (2007). Povezanost C-reaktivnog proteina sa ehokardiografskim parametrima hipertrofije i ishemijske bolesti srca u bolesnika koji se leče ponavljanim hemodijalizama. Med Pregl. LX (Suppl 2), 160–4.
- Akchurin OM, Kaskel F. (2015). Update on Inflammation in Chronic Kidney Disease. Blood Purif. 39(1), 84–92. DOI: 10.1159/000368940.
- Koenig W. (2003). C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant. 18(6), 1039–41. DOI: 10.1093/ndt/gfg103.
- Kanbay M, Perazella MA, Kasapoglu B, et al. (2010). Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purif. 29(1), 1–12. DOI: 10.1159/000245041.
- Locatelli F, Canaud B, Eckardt KU, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272–80. DOI: 10.1093/ndt/gfg074.
- Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. (2019). Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 32(1), 58–71. DOI: 10.1111/sdi.12745.
- Liakopoulos V, Roumeliotis S, Bozikas A, et al. (2019). Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence? Oxidative Med Cell Long. 2019, Article ID 9109473, 23 pages. DOI: 10.1155/2019/9109473.
- Zhang KY, Zuo L. (2014). Vitamin C supplementation in patients on maintenance dialysis. W J Clin Urol. 3(3), 344–50. DOI: 10.5410/wjcu.v3.i3.344.
- Coombes JS, Fassett RG. (2012). Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int. 81(3), 233–46. DOI: 10.1038/ki.2011.341.
- Gokbel H, Atalay H, Okudan N, et al (2011). Coenzyme Q10 and its Relation with Oxidant and Antioxidant System Markers in Patients with End-Stage Renal Disease. Ren Fail. 33(7), 677–81. DOI: 10.3109/0886022X.2011.589941.
- Den Hoedt CH, Bots ML, Grooteman MPC, et al. (2014). Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 86(2), 423–32. DOI: 10.1038/ki.2014.9.
- Panichi V, Scatena A, Rosati A, et al. (2015). High-volume online hemodiafiltration improves erythropoiesisstimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant. 30(4): 682–9. DOI: 10.1093/ndt/gfu345.
- Tarng DC, Huang TP, Liu TY, et al. (2000). Effect of vitamin E-bonded membrane on the 8-hydroxy 2,-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 58(2), 790–9. DOI: 10.1046/j.1523-1755.2000.00228.x.
- Andrulli S, Di Fillipo S, Manzoni C, et al. (2010). Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract 115(1), 82–9. DOI: 10.1159/000294281.
- Panagiotou A, Nalesso F, Zanella M, et al. Antioxidant Dialytic Approach with Vitamin E-Coated Membranes. In: Ronco C, Rosner MH. Eds. Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger, 2011; 171: 101–6.
- Panichi V, Rosati A, Paoletti S, et al. (2011). A vitamin E-coated polysulphone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif. 32(1), 7–14. DOI: 10.1159/000321369.
- Yang SK, Xiao L, Xu B, et al. (2014). Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis. Ren Fail. 36(5), 722–31. DOI: 10.3109/0886022X.2014.890858.
- Yamadera S, Nakamura Y, Inagaki M, et al. (2017). Vitamin E-Coated Dialyzer Inhibits Oxidative Stress. Blood Purif. 44(4), 288–93. DOI: 10.1159/000478971.
- D’Arrigo G, Baggetta R, Tripepi G, et al. (2017). Effects of vitamin E-Coated versus Conventiional Membranes in Chronic Hemodialysis Patients: A Systemic Review and Meta-Analysis. Blood Purif. 43(1–3), 101–22. DOI: 10.1159/000453444.
- Locatelli F, Andrulli S, Vigano SM, et al. (2017). Evaluation of the Impact of a New Synthetic Vitamin EBonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study. Blood Purif. 43(4), 338–45. DOI: 10.1159/000453442.
- Fishbane S, Singh AK, Cournoyer SH, et al. (2015). Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 30(12), 2019–26. DOI: 10.1093/ndt/gfv277.
- Gupta A, Lin V, Guss C, et al. (2015). Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 88(5), 1187–94. DOI: 10.1038/ki.2015.203.
- Shah HH, Hazzan AD, Fishbane S. (2016). Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialys. Semin Nephrol. 36(2), 124–9. DOI: 10.1016/j.semnephrol.2016.02.007.
- Fishbane S, Shah HH. (2017). Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis. Hemodialysis Int. 21(Suppl 1), 104–9. DOI: 10.1111/hdi.12554.
Language: English
Page range: 199 - 206
Submitted on: Jan 27, 2019
Accepted on: Feb 15, 2019
Published on: Aug 28, 2019
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2019 Svetlana Antic, Nevena Draginic, Tomislav Nikolic, Nevena Jeremic, Dejan Petrovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.